Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.
Bristol-Myers Squibb Co. and Pfizer Inc. say consolidated proceedings over the blood thinner Eliquis are winding down, following rulings by the U.S. District Court for the Southern District of New York ( Fortner v. Bristol-Myers Squibb Co. , 2017 BL 259098, S.D.N.Y., No. 17cv1562 (DLC), 7/26/17 ).
The July 26 and 27 rulings echo the court’s decision in May that federal law blocked, or preempted, a similar case in the multidistrict litigation. The decision also said the drug’s warnings were legally adequate.
One case remains, Pfizer spokeswoman Allyanna Anglim said in an email July 28. The briefing deadline for the plaintiff in that case hasn’t passed yet, she said.
There were 69 actions total in the Eliquis litigation, according to a Judicial Panel on Multidistrict Litigation statistics report.
Eliquis belongs to a new class of blood thinners designed to be easier to use than older drugs, such as warfarin. However, unlike warfarin, some of the newer blood thinners have no reversal agent.
Attorneys for plaintiff Sheila Fortner couldn’t be reached for comment.
Salim-Beasley LLC represented plaintiff Sheila Fortner.
DLA Piper LLC (US) represented Bristol-Myers and Pfizer.
To contact the reporter on this story: Martina Barash in Washington at MBarash@bna.com
To contact the editor responsible for this story: Steven Patrick at email@example.com
Full text at http://src.bna.com/re5.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)